Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune‐Mediated Thrombotic Thrombocytopenic Purpura

This publication has 9 references indexed in Scilit:

• Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP
  Blood Advances, 2024
• Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023
  International Journal of Hematology, 2023
• Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
  Journal of Thrombosis and Haemostasis, 2023
• Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis
  Blood Advances, 2021
• Redefining outcomes in immune TTP: an international working group consensus report
  Blood, 2021
• Pathophysiology of thrombotic thrombocytopenic purpura
  Blood, 2017
• Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
  Bone Marrow Transplantation, 2012
• Registry of 919 Patients with Thrombotic Microangiopathies across Japan: Database of Nara Medical University during 1998-2008
  Internal Medicine, 2010
• Novel monoclonal antibody‐based enzyme immunoassay for determining plasma levels of ADAMTS13 activity
  Transfusion, 2006